Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Science at AACR Aims to Overcome Cancer Care Barriers
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis